Esperion Therapeutics Secures $70,000,000 New Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=7707e52b-f53b-4f90-9dc8-49d51e5ef5c3&Preview=1 - Date
6/26/2013 - Company Name
Esperion Therapeutics - Mailing Address
46701 Commerce Center Drive Plymouth, MI 48170 - Company Description
Esperion Therapeutics, Inc. (NASDAQ: ESPR) discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called HDL Therapy, which is based on the Company’s understanding of high-density lipoprotein, or HDL, function. - Website
http://www.esperion.com - Transaction Type
IPO - Transaction Amount
$70,000,000 - Transaction Round
Undisclosed - Proceeds Purposes
Proceeds purposes are on file with company statements at the SEC. - M&A Terms
